Applicability and variability of liver stiffness measurements according to probe position

World Journal of Gastroenterology

Volumn 15, Issue 27, 2009, Pages 3398-3404

  Ingiliz, Patrick ^a   Chhay, Kim Pav ^a   Munteanu, Mona ^b   Lebray, Pascal ^a   Ngo, Yen ^a   Roulot, Dominique ^c   Benhamou, Yves ^a   Thabut, Dominique ^a   Ratziu, Vlad ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Biopredictive   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

Concordance; Fibroscan; Fibrotest; Liver fibrosis; Variability

Indexed keywords

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; BIOPSY TECHNIQUE; CONTROLLED STUDY; DISEASE MARKER; ELASTOGRAPHY; FEMALE; HEPATOGRAPHY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER EXAMINATION; LIVER FIBROSIS; LIVER STIFFNESS MEASUREMENT; MAJOR CLINICAL STUDY; MALE; POSITION; REFERENCE VALUE; BODY POSTURE; ELASTICITY; FIBROSIS; HISTOLOGY; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY;

BIOLOGICAL MARKER;

BIOLOGICAL MARKERS; ELASTICITY; ELASTICITY IMAGING TECHNIQUES; FIBROSIS; HUMANS; LIVER; MALE; MIDDLE AGED; POSTURE; REPRODUCIBILITY OF RESULTS;

EID: 70349574440     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.3398     Document Type: Article

References (27)

1. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-3694
2. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003; 37: 972-974
3. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, El-Kamary SS, Sulkowski M, Bass EB. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36: S161-S172
4. Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology 2005; 128: 1146-1148; author reply 1148
5. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40
6. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Ledinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350
7. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974
8. Castera L, Denis J, Babany G, Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J Hepatol 2007; 46: 528-529; author reply 529-530
9. La Haute Autorité de Santé (HAS) in France - The HAS recommendations for the management of the chronic hepatitis C using non-invasive biomarkers. Available from: URL: http://www.has-sante.fr/ portail/display.jsp?id=c_476486
10. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-973
11. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Ledinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-408
12. Kettaneh A, Marcellin P, Douvin C, Poupon R, Ziol M, Beaugrand M, de Ledinghen V. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007; 46: 628-634
13. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713
14. Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, Brunetto MR. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14: 360-369
15. Kim KM, Choi WB, Park SH, Yu E, Lee SG, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol 2007; 42: 382-388
16. Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48: 606-613
17. Tanné F, El Saouda R, Bessaguet C, Cholet F, Andlauer E, Delalande AH, Robaszkiewicz M, Gouérou H, Nousbaum JB. A Study to evaluate the variability of elastometric measurements for the diagnosis of hepatic fibrosis. Gastroenterol Clin Biol 2006; 29: A6
18. Munteanu M, Ngo Y, De Torres, Messous D, Lebray P, Ratziu V, Poynard T. Three-dimensional and metabolic variability of Fibroscan (transient elastography) measures in healthy volunteers. Gastroenterology 2006; 130: A768
19. Lucidarme D, Foucher J, Le Bail B, Castera L, Villars S, Forzy G, Filoche B, Couzigou P, de Lédinghen V. Ratio interquartile range/ median value of liver stiffness measurement is a key factor of accuracy of transient elastography (FIBROSCAN®) for the diagnosis of liver fibrosis. Hepatology 2007; 46: A318
20. Imbert-Bismut F, Messous D, Thibault V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004; 42: 323-333
21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174
23. Hintze JL. NCSS 2007 User Guide. Number Cruncher Statistical Systems software NCSS, Kaysville, Utah 2007
24. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457
25. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, Lebray P, Thibault V, Benhamou Y, Moussalli J, Ratziu V, Poynard T. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-1896
26. Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, Lebray P, Thabut D, Morra R, Messous D, Charlotte F, Imbert-Bismut F, Bonnefont-Rousselot D, Moussalli J, Ratziu V, Poynard T. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS One 2008; 3: e2573
27. Poynard T, Ingiliz P, Elkrief L, Munteanu M, Lebray P, Morra R, Messous D, Bismut FI, Roulot D, Benhamou Y, Thabut D, Ratziu V. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One 2008; 3: e3857